Facebook Twitter LinkedIn YouTube Instagram

To navigate the following site navigation expect to utilize the tab key to move through items sequentially. The spacebar or enter keys can be utilized to interact with items that open sub-navigation.

The next tab will be the search box toggle. Hit enter to open the search, focus will automatically shift to the search bar. Type a letter into the search input and suggested results will appear.

Drug

Belimumab (Benlysta)

Status:

Phase 3

Condition:

Systemic Sclerosis ILD

Intervention Type:

Subcutaneous (SC) Injection

Funder Type:

Industry

Drug Details

Belimumab is an Anti-B lymphocyte stimulator (BLys) monoclonal antibody.

Study Purpose

This study investigates the efficacy and safety of belimumab compared to placebo, in addition to standard therapy, for the treatment of participants with systemic sclerosis-associated interstitial lung disease (SSc-ILD). The study will evaluate the effect of belimumab treatment on lung function as well as on extra-pulmonary disease manifestations, including skin thickening and general symptoms, such as fatigue, that impact quality of life (QoL).

Find a Clinical Trial